Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for prevention of etomidate injection pain
IRCT20160307026950N38Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ondansetron in Injection site pain (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Pain caused by Etomidate. Started Oct 2021; status: completed.
02
Drugs
ondansetron
03
Conditions
Injection site pain
Beyond the preview
Go deeper on IRCT20160307026950N38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N38.